📊 KYNB Key Takeaways
Is Kyntra Bio, Inc.. (KYNB) a Good Investment?
Kyntra Bio exhibits severe financial distress with negative stockholders equity of -$43.8M, indicating balance sheet insolvency. The company generates minimal revenue ($3.7M) against massive operating losses (-$13.8M), while carrying $75M in long-term debt it cannot service from operations (interest coverage: -5.7x). With negative free cash flow of -$13.9M annually and current cash reserves of $37M, the company has approximately 2.7 years of runway before insolvency unless it achieves transformative clinical or commercial milestones.
Headline profitability is driven by non-operating/one-time items while core operations remain deeply unprofitable, evidenced by a large operating loss and negative free cash flow on flat revenue. Despite a solid near-term liquidity buffer, negative equity, high leverage, and weak interest coverage create elevated financial risk and potential dilution or refinancing pressure.
Kyntra Bio, Inc.. Key Strengths (KYNB)
- Strong short-term liquidity position with current ratio of 3.61x and quick ratio of 3.48x
- Net income loss improved 485.6% year-over-year, suggesting operational efficiency gains despite losses
- Maintains $37M in cash reserves providing near-term operational flexibility
- Strong near-term liquidity (current ratio >3x, sizable cash)
- Low capital intensity (minimal capex)
- Some revenue base despite early stage
KYNB Stock Risks: Kyntra Bio, Inc.. Investment Risks
- Balance sheet insolvency with negative stockholders equity of -$43.8M; equity value theoretically zero or negative
- High debt burden ($75M) cannot be serviced from operations; interest coverage is -5.7x indicating inability to pay interest from earnings
- Significant cash burn of -$13.9M annually with minimal revenue of $3.7M; company consumes cash for every dollar of revenue generated
- Negligible revenue growth (0.0% YoY) indicates lack of commercial momentum or market traction
- Large and persistent operating losses
- Negative stockholders' equity indicates fragility
- High debt with poor interest coverage and refinancing risk
Key Metrics to Watch
- Cash balance depletion rate and months of runway remaining
- Operating cash flow trend and path to positive FCF
- Revenue growth acceleration and gross margin development
- Debt restructuring events, covenant violations, or refinancing activities
- Clinical trial progression or regulatory milestones indicating value creation potential
- Operating cash flow/burn rate
- Interest coverage and debt maturities
Kyntra Bio, Inc.. (KYNB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.61x current ratio provides a solid financial cushion.
KYNB Profit Margin, ROE & Profitability Analysis
KYNB vs Healthcare Sector: How Kyntra Bio, Inc.. Compares
How Kyntra Bio, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kyntra Bio, Inc.. Stock Overvalued? KYNB Valuation Analysis 2026
Based on fundamental analysis, Kyntra Bio, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kyntra Bio, Inc.. Balance Sheet: KYNB Debt, Cash & Liquidity
KYNB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kyntra Bio, Inc..'s revenue has declined by 88% over the 5-year period, indicating business contraction. The most recent EPS of $-11.89 indicates the company is currently unprofitable.
KYNB Revenue Growth, EPS Growth & YoY Performance
KYNB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.7M | $4.6M | $1.15 |
| Q3 2025 | $123.0K | -$17.1M | $-4.25 |
| Q2 2025 | $998.0K | -$3.0M | $-0.73 |
| Q1 2025 | $2.7M | $4.6M | $0.05 |
| Q3 2024 | $40.1M | -$17.1M | $-0.17 |
| Q2 2024 | $44.3M | -$15.5M | $-0.16 |
| Q1 2024 | $36.2M | -$32.9M | $-0.33 |
| Q3 2023 | $15.7M | -$63.6M | $-0.65 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Kyntra Bio, Inc.. Dividends, Buybacks & Capital Allocation
KYNB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kyntra Bio, Inc.. (CIK: 0000921299)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KYNB
What is the AI rating for KYNB?
Kyntra Bio, Inc.. (KYNB) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 79% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KYNB's key strengths?
Claude: Strong short-term liquidity position with current ratio of 3.61x and quick ratio of 3.48x. Net income loss improved 485.6% year-over-year, suggesting operational efficiency gains despite losses. ChatGPT: Strong near-term liquidity (current ratio >3x, sizable cash). Low capital intensity (minimal capex).
What are the risks of investing in KYNB?
Claude: Balance sheet insolvency with negative stockholders equity of -$43.8M; equity value theoretically zero or negative. High debt burden ($75M) cannot be serviced from operations; interest coverage is -5.7x indicating inability to pay interest from earnings. ChatGPT: Large and persistent operating losses. Negative stockholders' equity indicates fragility.
What is KYNB's revenue and growth?
Kyntra Bio, Inc.. reported revenue of $3.7M.
Does KYNB pay dividends?
Kyntra Bio, Inc.. does not currently pay dividends.
Where can I find KYNB SEC filings?
Official SEC filings for Kyntra Bio, Inc.. (CIK: 0000921299) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KYNB's EPS?
Kyntra Bio, Inc.. has a diluted EPS of $-3.76.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is KYNB's fundamental grade?
Based on our AI fundamental analysis in June 2026, Kyntra Bio, Inc.. has a C grade with 79% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is KYNB stock overvalued or undervalued?
Valuation metrics for KYNB: ROE of N/A (sector avg: 15%), net margin of -406.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is KYNB's AI grade for 2026?
Our dual AI analysis gives Kyntra Bio, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KYNB's free cash flow?
Kyntra Bio, Inc..'s operating cash flow is $-13.9M, with capital expenditures of $0.0. FCF margin is -371.5%.
How does KYNB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -406.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 3.61 (avg: 2).